Dr. Leighmin James Lu, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 9150 Estate Thomas, Suite 105 Vi Medical Foundation Bldg, St Thomas, VI 00801 Phone: 340-774-6947 Fax: 340-777-9522 |
Dr. James Dallas Nelson, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: Upperhavensite Bld3 305, St Thomas, VI 00802 Phone: 340-774-3633 Fax: 340-776-2552 |
Tracy Lynn Genovese, Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 4605 Tutu Park Mall Ste 207, St Thomas, VI 00802 Phone: 340-775-3700 |
News Archive
Wellmark Blue Cross and Blue Shield's proposed 11 percent health insurance premium increase is excessive, two experts have concluded. The company, which insures three-quarters of Iowans who buy their own policies, already raised premiums on those plans an average of 18 percent last spring. Wellmark sparked outcries when it announced in November that it wants to raise those rates again in order to keep up with rising prices and increased use of medical care (Leys, 1/7).
The frequency of alpha brain waves can be used as a measure of an individual's vulnerability to developing and experiencing pain, researchers at the University of Birmingham in the UK and University of Maryland in the US have discovered.
A partnership was announced Wednesday between insurers UnitedHealthcare, Aetna and Humana and the Health Care Cost Institute to create a payment database that will be available at no cost to the public.
WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its manufacturing subsidiary, Shanghai SynTheAll Pharmaceuticals Co. Ltd. (STA) passed the ISO 14001: 2004 inspection conducted by SGS Group on July 1 and received formal ISO 14001 certification on July 30.
The sensitivity of the GLP-1 hormone, which is secreted by the gastrointestinal tract, can predict the metabolic efficacy of a gastric bypass. The use of a GLP1 challenge could thus function as a novel predictive biomarker for personalized treatment of type 2 diabetes and obesity.
› Verified 1 days ago